On August 19, 2026, the U.S. Food and Drug Administration approved Regeneron’s PASATRU™ (garetosmab-grts) for the treatment of adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder characterized by progressive heterotopic ossification (HO), the formation of bone in muscles, tendons, ligaments, and other connective tissues. According to Regeneron, PASATRU…
